作者
Abdelrahman Y Fouda, Zhimin Xu, Jutamas Suwanpradid, Modesto Rojas, Esraa Shosha, Tahira Lemtalsi, Chintan Patel, Ji Xing, Syed A Zaidi, Wenbo Zhi, Brain K Stansfield, Paul Ning-Man Cheng, S Priya Narayanan, R William Caldwell, Ruth B Caldwell
发表日期
2022/8/29
期刊
Cell Death & Disease
卷号
13
期号
8
页码范围
745
出版商
Nature Publishing Group UK
简介
Current therapies for treatment of proliferative retinopathy focus on retinal neovascularization (RNV) during advanced disease and can trigger adverse side-effects. Here, we have tested a new strategy for limiting neurovascular injury and promoting repair during early-stage disease. We have recently shown that treatment with a stable, pegylated drug form of the ureohydrolase enzyme arginase 1 (A1) provides neuroprotection in acute models of ischemia/reperfusion injury, optic nerve crush, and ischemic stroke. Now, we have determined the effects of this treatment on RNV, vascular repair, and retinal function in the mouse oxygen-induced retinopathy (OIR) model of retinopathy of prematurity (ROP). Our studies in the OIR model show that treatment with pegylated A1 (PEG-A1), inhibits pathological RNV, promotes angiogenic repair, and improves retinal function by a mechanism involving decreased expression of …
学术搜索中的文章
AY Fouda, Z Xu, J Suwanpradid, M Rojas, E Shosha… - Cell Death & Disease, 2022